Wockhardt gains 2% on USFDA nod for anti-bacterial tablets

Wockhdart is trading higher by 2% at Rs 355 after the company received the final approval from the United States Food and Drug Administration (USFDA) for marketing the Levofloxacin tablets, used for treating bacterial infections, in the American market.

“Levofloxacin tablets in strengths of 250 mg, 500 mg and 750 mg. Besides Levofloxacin tablets, the company has also launched Donepezil tablets and Venlafaxine extended-release capsules in the US market recently,” the pharmaceutical company said in a statement.

“According to IMS, the combined brand sales of all three products in the US market is over $6 billion,” the company said.

The stock opened at Rs 355 and touched a high of Rs 363 on the NSE. A total of 48,676 shares have changed hands on the counter till 0948 hours.